Overexpression of the nuclear factor-kappa B (p65) in association with local failure in patients with head and neck carcinoma undergong radiotherapy or chemoradiotherapy
Por:
Quintana A., Avilés F.X., Terra X., Alcolea S., Camacho M., Quer M., Vila L., León X.
Publicada:
1 ene 2013
Resumen:
Background The aim of this study was to evaluate nuclear factor-kappa B (NF-?B) expression as a biologic marker to predict local control in patients with head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy or chemoradiotherapy. Methods The mRNA expression levels of the NF-?B family genes were determined with real-time-polymerase chain reaction in 77 patients with HNSCC treated with radiotherapy or chemoradiotherapy. Results The mRNA NF-?B (p65) expression in pretreatment tumors was significantly related to local control (p =.03). The 5-year local recurrence-free survival rate in patients with low-level NF-?B (p65) expression (n = 42) was 79.9%, and in patients with a high level of expression it was 42.1% (p =.001). In a multivariate analysis, the mRNA NF-?B (p65) expression level was the only variable related to local control of the tumor. Conclusion Expression of the NF-?B (p65) gene may be a radiosensitivity marker for patients with a HNSCC. © 2012 Wiley Periodicals, Inc.
Filiaciones:
Quintana A.:
Otorhinolaryngology Department, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Avilés F.X.:
Otorhinolaryngology Department, Universitat Rovira i Virgili, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
Terra X.:
Grup d'Estudi de Malalties Metabòliques Asociades A Insulin Resistència (GEMMAIR), Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Tarragona, Spain
Alcolea S.:
Laboratory of Angiology, Vascular Biology and Inflammation, Institute of Biomedical Research (IIB Sant Pau), Barcelona, Spain
Camacho M.:
Laboratory of Angiology, Vascular Biology and Inflammation, Institute of Biomedical Research (IIB Sant Pau), Barcelona, Spain
Quer M.:
Otorhinolaryngology Department, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Vila L.:
Laboratory of Angiology, Vascular Biology and Inflammation, Institute of Biomedical Research (IIB Sant Pau), Barcelona, Spain
León X.:
Otorhinolaryngology Department, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
|